Novartis' chief executive, Daniel Vasella, says that the firm plans to undertake significant restructuring in an effort to reduce bureaucracy. In an interview with the Wall Street Journal, Dr Vasella said that the Swiss drug major must become more streamlined in order to handle new challenges facing the pharmaceutical industry.
Dr Vasella said that the plans would involve jobs losses on top of those previously announced by the firm (Marketletter October 29), but declined to say how many.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze